SAR302503

This page shows the latest SAR302503 news and features for those working in and with pharma, biotech and healthcare.

Jakafi cleared for bone marrow disorder by FDA

pacritinib. Sanofi was forced to discontinue development of its fedratinib (SAR302503) candidate after cases of a rare form of encephalopathy were seen in late-stage trials.

Latest news

Sanofi pulls development of blood cancer drug

The France-based pharma company said the reason to pull fedratinib – also known as SAR302503 – was due to the drug's link to an increased risk of the brain disorder
Jakavi shows long-term survival benefit in myelofibrosis

Meanwhile, Jakavi will have the market to itself for at least as a couple of years, as rival JAK inhibitors such as Sanofi's SAR302503 and Gilead Sciences' CYT387 are still
Sanofi plans to file JAK2 inhibitor after positive phase III

Aiming for approval in blood cancer myelofibrosis. Sanofi has started to prepare for regulatory filings of its blood cancer treatment SAR302503 following positive results in a pivotal study. ... In the trial, patients with intermediate-2 or high-risk
Sanofi has 65 new compounds in development, says R&D chief

Elias Zerhouni to showcase pharma company's pipeline, promises costs will be rigorously managed

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

Pharma deals during November 2013

While Sanofi announced this month that it had discontinued clinical trials of fedratinib (SAR302503), an investigational JAK2 inhibitor, Baxter entered an exclusive global agreement (headline value $172m) to develop and commercialise

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

The search for treatments for Parkinson’s disease: The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.: Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials: As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...